|Day Low/High||29.14 / 29.90|
|52 Wk Low/High||20.05 / 35.79|
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
For the First Time, AJCC Adds Molecular Markers to Staging Criteria, Including Oncotype DX along with Estrogen Receptor (ER), Progesterone Receptor (PR), and HER2 Status
Presentations at 2016 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) Highlight Unique Value of Oncotype DX in Tailoring Treatment Across the Breast Cancer Patient Journey
In recent trading, shares of Genomic Health Inc have crossed above the average analyst 12-month target price of $31.94, changing hands for $32.26/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
Oncotype DX® Genomic Prostate Score™ Becomes Only Test Validated to Measure All Four Critical Features of Tumor Aggressiveness
Unique Prospective Study Provides Real-world Evidence Demonstrating Use of Oncotype DX® Genomic Prostate Score™ Saves Over $2,000 per Patient by Optimizing Care and Healthcare Spending
Data Presented for First Time at ESMO 2016 Congress Highlight Company's Commitment to Delivering Rigorous, Clinically Actionable Liquid-based Tests for Late-stage Cancer Patients
Two Large International Studies Underscore Ability of Oncotype DX to Identify Patients with Node-positive Breast Cancer Who Can Forego Chemotherapy and Its Side Effects
Broad Range of Presentations Includes Oncotype SEQ™ Liquid Biopsy Analytical Validation, New Outcomes Data in Invasive Breast Cancer and Studies in Node-positive Disease
These five stocks could be toxic for your portfolio in the month ahead.
Investors considering a purchase of Genomic Health Inc stock, but cautious about paying the going market price of $26.70/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the March 2017 put at the $22.50 strike, which has a bid at the time of this writing of $1.25.
Trade-Ideas LLC identified Genomic Health (GHDX) as a weak on high relative volume candidate
Validation Study Led by Memorial Sloan Kettering Cancer Center, Published in JAMA Oncology, Demonstrated Patients with AR-V7 Positive Circulating Tumor Cells Have Significantly Better Outcomes if Treated with Chemotherapy versus Hormonal Treatments
Genomic Health Provides Unique New Option for Non-invasive Tumor Assessment in Later-stage Disease, Transforming Cancer Care Across the Patient Journey
Study Showed Node-negative and Node-positive Patients with Low Oncotype DX® Breast Recurrence Score™ Results - the Vast Majority Treated without Chemotherapy - Had Excellent Breast Cancer Survival
Four New Analyses of SEER Registry Provide Additional Evidence that Oncotype DX Accurately Predicts Patient Outcomes in Node-negative and Node-positive Breast Cancer and Reinforce Its Value in Older Women
Presentations in Breast and Prostate Cancers Underscore Genomic Health's Industry-leading Commitment to Help Physicians and Patients Optimize Cancer Treatment Decisions
Findings Confirm that Oncotype DX May Help Identify Breast Cancer Patients with Greatest Potential to Benefit from Extended Hormonal Therapy
Trade-Ideas LLC identified Genomic Health (GHDX) as a strong on high relative volume candidate